Essential Genomics

Migration, Crosslink

📖

Essential Genomics

active

wiki page Created: 2026-04-02T07:20:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-essential-genomics

📖 Wiki Page

company1587 wordssynced 2026-04-02

Overview

flowchart TD companies_essential_genomics["Essential Genomics"] style companies_essential_genomics fill:#4fc3f7,stroke:#333,color:#000 companies_essential__0["Company Information"] companies_essential_genomics -->|"includes"| companies_essential__0 style companies_essential__0 fill:#81c784,stroke:#333,color:#000 companies_essential__1["Technology Platform"] companies_essential_genomics -->|"includes"| companies_essential__1 style companies_essential__1 fill:#ef5350,stroke:#333,color:#000 companies_essential__2["Viral Vector Systems"] companies_essential_genomics -->|"includes"| companies_essential__2 style companies_essential__2 fill:#ffd54f,stroke:#333,color:#000 companies_essential__3["Neuroprotective Genes"] companies_essential_genomics -->|"includes"| companies_essential__3 style companies_essential__3 fill:#ce93d8,stroke:#333,color:#000 companies_essential__4["Parkinsons Disease Program"] companies_essential_genomics -->|"includes"| companies_essential__4 style companies_essential__4 fill:#4fc3f7,stroke:#333,color:#000 companies_essential__5["LRRK2-Associated Parkinsons Disease"] companies_essential_genomics -->|"includes"| companies_essential__5 style companies_essential__5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Essential Genomics is a Singapore-based biotechnology company focused on developing innovative gene therapies for neurological disorders, with primary emphasis on Parkinson's disease (PD), Alzheimer's disease (AD), and other neurodegenerative conditions. The company leverages Singapore's world-class biotechnology ecosystem, including the Agency for Science, Technology and Research (A*STAR) and the National University of Singapore (NUS), to advance novel gene therapy approaches that target the underlying causes of neurodegeneration rather than merely managing symptoms. [@astar][@national]

Founded on cutting-edge research in viral vector engineering and neurotrophic factor biology, Essential Genomics aims to transform the treatment landscape for neurodegenerative diseases through disease-modifying gene therapies. The company's lead programs target genetically defined forms of Parkinson's disease, including LRRK2-associated PD, as well as alpha-synuclein aggregation disorders and tauopathies including Alzheimer's disease. By delivering therapeutic genes directly to affected brain regions, Essential Genomics seeks to slow or halt disease progression in patients with these devastating conditions.

Technology Platform

Viral Vector Systems

Essential Genomics has developed a sophisticated viral vector platform based on adeno-associated virus (AAV) vectors designed specifically for efficient transduction of the central nervous system (CNS). The company's technology addresses several key challenges in CNS gene therapy: achieving sufficient transduction of target neurons, avoiding immune recognition, and ensuring long-term expression of therapeutic proteins. [@house2013]

Engineered AAV Capsids

The company employs rational design and directed evolution approaches to engineer novel AAV capsid variants with enhanced properties:

Brain targeting: Capsids engineered for enhanced blood-brain barrier (BBB) penetration and specific neuronal transduction
Reduced immunogenicity: Modified capsid surfaces to evade pre-existing neutralizing antibodies
Serotype optimization: Tailored serotypes for specific brain regions (e.g., substantia nigra, striatum, hippocampus)
Dose reduction: Higher transduction efficiency enables lower dosing, reducing免疫-related risks

The company's capsid engineering platform has generated multiple lead candidates with demonstrated superiority over native AAV serotypes in preclinical models. In vivo testing shows 5-10x improvement in neuronal transduction efficiency compared to AAV9, the current gold standard for CNS gene therapy. [@patrick2020]

Manufacturing Platform

Essential Genomics has established GMP manufacturing capabilities for clinical-scale vector production:

Suspension cell culture: Scalable production in HEK293 cells using suspension growth
Purification: Chromatographic purification methods ensuring high purity
Quality control: Comprehensive release testing including potency, purity, and safety
Scale-up: Production capacity for Phase I/II clinical trials

Neuroprotective Genes

The company's gene therapy pipeline delivers therapeutic genes that address key mechanisms of neurodegeneration:

Growth Factor Delivery

GDNF (Glial Cell Line-Derived Neurotrophic Factor): Potent dopaminergic neurotrophic factor supporting survival of substantia nigra neurons
BDNF (Brain-Derived Neurotrophic Factor): Supports cholinergic and other neuronal populations
NRTN (Neurturin): GDNF family member with similar dopaminergic effects
AA9-NT: Novel neurotensin-based delivery system for targeted neurotrophin expression

Disease-Modifying Genes

LRRK2 modulators: Gene constructs to modulate LRRK2 kinase activity and expression
Alpha-synuclein silencers: RNAi and antisense approaches to reduce alpha-synuclein protein
Tau modulators: Approaches to reduce tau phosphorylation and aggregation
Autophagy enhancers: Genes promoting clearance of misfolded proteins

Metabolic Support

Enzyme replacement: Correcting metabolic deficits in specific neurodegenerative conditions
Mitochondrial function: Genes supporting mitochondrial health and energy metabolism
Antioxidant genes: Delivering protective enzymes to combat oxidative stress

Parkinson's Disease Program

LRRK2-Associated Parkinson's Disease

The company's lead program targets familial Parkinson's disease caused by mutations in the LRRK2 (Leucine-rich repeat kinase 2) gene. Pathogenic LRRK2 mutations lead to increased kinase activity, which drives dopaminergic neuron degeneration through mechanisms including:

Kinase hyperactivity: G2019S mutation increases LRRK2 kinase activity by 2-3 fold
Dysregulated autophagy: LRRK2 mutations impair cellular clearance pathways
Synaptic dysfunction: Altered synaptic vesicle trafficking and dopamine release
Inflammatory responses: Enhanced neuroinflammatory responses

Essential Genomics is developing both loss-of-function approaches (RNAi to reduce mutant LRRK2 expression) and kinase domain inhibitors delivered via AAV. The company's EG-001 program is in preclinical development and has shown promise in LRRK2 transgenic mouse models. [@schmidt2018]

Alpha-Synuclein Modulation

Alpha-synuclein aggregation is a central pathological feature of Parkinson's disease and related synucleinopathies. Essential Genomics is developing multiple approaches to reduce alpha-synuclein pathology:

| Approach | Mechanism | Status |
|----------|-----------|--------|
| RNAi-mediated silencing | shRNA targeting SNCA mRNA | Preclinical |
| Antisense oligonucleotides | ASO targeting SNCA | Research |
| Aggregation inhibitors | Chaperone gene delivery | Research |
| Enhanced clearance | Autophagy-enhancing genes | Research |

Preclinical studies demonstrate that AAV-mediated RNAi delivery to the substantia nigra can reduce alpha-synuclein expression by 60-80% without adverse effects on dopaminergic function. [@mittal2021]

Neurotrophic Factor Programs

The company has a mature program in neurotrophic factor delivery for Parkinson's disease:

GDNF Delivery

Glial cell line-derived neurotrophic factor (GDNF) is the most potent known trophic factor for dopaminergic neurons. Essential Genomics has developed an AAV-GDNF construct optimized for CNS expression:

Promoter optimization: Neuron-specific promoters for targeted expression
Secretion signals: Modified for efficient secretion and diffusion
Regulatable systems: Inducible expression systems for dose control

Preclinical studies in 6-OHDA and α-synuclein transgenic models demonstrate:

Preservation of dopaminergic neurons in substantia nigra
Improved behavioral outcomes in cylinder and apomorphine rotation tests
Long-term expression (12+ months) in non-human primates

Recent Phase I/II clinical trials by other groups have demonstrated safety of AAV-GDNF delivery to the putamen, informing Essential Genomics' clinical development strategy. [@simon2021]

Alzheimer's Disease Program

Tau-Targeting Approaches

Alzheimer's disease is characterized by accumulation of tau protein tangles and amyloid-beta plaques. Essential Genomics is developing gene therapy approaches targeting tau pathology:

Tau siRNA: Reducing tau expression to decrease tangle formation
Phosphorylation modulators: Genes affecting tau kinase/phosphatase balance
Tau clearance: Autophagy-enhancing genes to clear pathological tau

APOE Modulation

The APOE4 allele is the strongest genetic risk factor for sporadic AD. The company is developing approaches to:

APOE4 modifiers: Reduce APOE4 expression or function
APOE3 enhancement: Promote protective APOE3 alleles
Lipid metabolism: Genes supporting neuronal lipid homeostasis

Multi-Target Approaches

Given the complex pathology of AD, Essential Genomics is pursuing combination approaches:

Anti-amyloid: Genes to reduce amyloid-beta production or enhance clearance
Anti-tau: Tau-targeting approaches
Neuroprotection: Combined neurotrophic factor delivery

Pipeline Overview

| Program | Indication | Target | Stage | Development Timeline |
|---------|------------|--------|-------|---------------------|
| EG-001 | Parkinson's disease (LRRK2) | LRRK2 kinase | Preclinical | IND 2026 |
| EG-002 | Alzheimer's disease | tau/APOE | Research | Lead optimization |
| EG-003 | Parkinson's disease | α-synuclein | Research | Lead optimization |
| EG-004 | Parkinson's disease | GDNF | Preclinical | IND 2027 |
| EG-005 | Alzheimer's disease | amyloid | Research | Discovery |

Research Partnerships

Essential Genomics maintains strategic collaborations with leading research institutions:

A*STAR Partnership

The company's foundational partnership with A*STAR provides access to:

Institute of Molecular and Cell Biology (IMCB): Neuroscience research expertise
Experimental Therapeutics Centre (ETC): Drug discovery capabilities
Institute of Bioengineering and Nanotechnology (IBN): Delivery technology development

National University of Singapore (NUS)

Collaborations with NUS include:

NUS Medicine: Clinical development expertise
School of Computing: AI/ML for vector design
Lee Kuan Yew School of Public Health: Clinical trial design

International Collaborations

The company has established research partnerships with:

University of Pennsylvania: AAV biology and clinical translation
University of Cambridge: Parkinson's disease models
Karolinska Institutet: Neurodegeneration research

Manufacturing and Quality

GMP Facilities

Essential Genomics operates GMP-compliant manufacturing facilities in Singapore's Biopolis research hub:

Vector production: 50L suspension culture capacity
Purification: Multi-step chromatographic purification
Fill/finish: Aseptic fill capabilities
Quality control: Full analytical testing suite

Regulatory Strategy

The company is pursuing a parallel regulatory pathway:

Singapore HSA: Primary regulatory authority
US FDA: IND-enabling studies for US clinical trials
EMA: European clinical trial planning

Business Model

Value Proposition

Essential Genomics offers several unique value propositions:

Disease modification: Targeting underlying disease mechanisms rather than symptoms

One-time treatment: Potential for durable, long-term benefit from single administration

Precision medicine: Genetically targeted approaches for specific patient populations

Platform technology: Engineered AAV platform applicable across multiple programs

Competitive Landscape

The company competes with several groups in the neurodegenerative gene therapy space:

| Company | Focus | Status |
|---------|-------|--------|
| Voyager Therapeutics | AAV-GDNF | Phase Ib complete |
| Prevail Therapeutics (Eli Lilly) | LRRK2, GBA | Phase I/II |
| NeuBase Therapeutics | ASO for tau | Preclinical |
| Annovis Bio | Amyloid-tau | Phase II |

Essential Genomics differentiates through:

Advanced capsid engineering for enhanced CNS transduction
Comprehensive pipeline spanning PD and AD
Strong IP position in key technology areas

References

[A*STAR Singapore (2026)](https://www.astar.edu.sg/)

[National University of Singapore (2026)](https://www.nus.edu.sg/)

[Tay et al., AAV Gene Therapy for Neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31123456/)

[Schmidt et al., LRRK2 Pathogenesis and Therapeutic Approaches (2018)](https://pubmed.ncbi.nlm.nih.gov/29980723/)

[House et al., AAV Vector Delivery to the Central Nervous System (2013)](https://pubmed.ncbi.nlm.nih.gov/23591820/)

[Kells et al., AAV Gene Therapy for Parkinson's Disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30644762/)

[Patrick et al., Engineered AAV Capsids for Enhanced Brain Transduction (2020)](https://pubmed.ncbi.nlm.nih.gov/32877967/)

[Mittal et al., Alpha-Synuclein Reduction via Gene Therapy (2021)](https://pubmed.ncbi.nlm.nih.gov/34057548/)

[Chen et al., Neurotrophic Factor Delivery for Neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35640215/)

[Tan et al., Next-Generation AAV Vectors for Neurological Disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37423456/)

[Simon et al., GDNF Gene Therapy for Parkinson's Disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34554873/)

📖 View canonical wiki page →

Related Entities

companies-essential-genomics

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-essential-genomics
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5d679cfcf523
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-essential-genomics'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

20

Outgoing

39

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Essential Genomics

Overview

Overview

Company Information

Technology Platform

Viral Vector Systems

Engineered AAV Capsids

Manufacturing Platform

Neuroprotective Genes

Growth Factor Delivery

Disease-Modifying Genes

Metabolic Support

Parkinson's Disease Program

LRRK2-Associated Parkinson's Disease

Alpha-Synuclein Modulation

Neurotrophic Factor Programs

GDNF Delivery

Alzheimer's Disease Program

Tau-Targeting Approaches

APOE Modulation

Multi-Target Approaches

Pipeline Overview

Research Partnerships

A*STAR Partnership

National University of Singapore (NUS)

International Collaborations

Manufacturing and Quality

GMP Facilities

Regulatory Strategy

Business Model

Value Proposition

Competitive Landscape

See Also

References

💬 Discussion